A proposed class action lawsuit accuses Oura of misleading buyers about how well its smart rings track sleep, alleging the devices can't actually measure the physiological signals needed to assess sleep quality or identify sleep stages. The complaint, filed Thursday by Clarkson Law Firm in San Francisco, claims Oura's rings instead depend on AI-generated guesses that have "a coin flip's chance of being correct." The suit follows years of user complaints online, with customers saying the device told them their sleep was optimal when they felt poorly rested, and questioning whether it can truly monitor sleep cycles.
The lawsuit alleges Oura marketed rings priced at $300 and higher by claiming they could see what only hospital sleep labs can detect, including all four stages of sleep. According to the complaint, Oura told customers its devices achieved 79% accuracy in their measurements, and more recently stated the rings delivered 95% sleep-staging accuracy when compared with clinical sleep labs. The company described its product as "built for accuracy" and offering "unparalleled accuracy," the suit says. The complaint contends Oura can't measure sleep or cycles because "sleep happens in the brain, not on one's finger," noting that determining exact sleep stages requires electrodes on the scalp and sensors on the eyes, technology only available in hospitals or clinical settings.
"When people rely on a device to guide decisions about their health, misinformation cannot be tolerated," said Ryan Clarkson, co-founder and managing partner at Clarkson Law Firm, in a press release. He added that Oura users trust the numbers displayed reflect reality, and that people structure their schedules, interpret how they feel, and design their lives around inaccurate data produced by these devices. The complaint argues that marketing an imprecise sleep tracker as exact and dependable is dangerous because consumers believe it and modify their behavior as a result. Oura didn't immediately respond to a request for comment from TechCrunch.
The lawsuit calls on Oura to halt what it describes as deceptive advertising of capabilities the wearables don't actually possess. It seeks court orders preventing Oura from continuing to misrepresent its products, along with reimbursement for consumers who bought the devices based on those allegedly false representations. The complaint reflects growing scrutiny of wearable health devices that promise clinical-grade insights but rely on algorithms rather than the direct physiological monitoring used in medical settings, raising questions about whether accuracy claims made by consumer tech companies can match the standards of hospital equipment. As wearables become more central to how people understand their health, the gap between marketed precision and actual performance may prove costly for manufacturers who overstate their technology's limits. For device makers navigating this territory, the tension between ambitious marketing and engineering reality presents a challenge that courtrooms, not just product reviews, may ultimately resolve.